Company intelligence / Profile preview

Kureha

Ownership: Private
Employees: ~4374
Development stage: Commercial

Overview

Kureha has developed and commercialized several pharmaceutical products, including "Krestin" for cancer immunotherapy and "Kremezin" for chronic kidney disease. Some pipeline programs have been discontinued, while others are in various stages of development or regulatory review.

Therapeutic areas: OncologyRheumatologyImmunologyNephrology
Modalities: Small moleculeBiologicMonoclonal antibody
Industry: Biotech

Drug pipeline

5 assets

activated charcoal

4 more assets in the full pipeline.

Request access →

Partnerships

Claros Technologies (PFAS remediation technology partnership)Celanese (Fortron Industries joint venture for polyphenylene sulfide production)

Beyond the preview

Go deeper on Kureha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kureha.

Explore the full profile